10 Best Dividend Monarchs to Invest in Now

7. Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holders: 66

Abbott Laboratories (NYSE:ABT) ranks seventh on our list of the best Dividend Monarchs. The American medical device company provides services and products in diagnostics, nutrition, and established pharmaceuticals. The company recently announced that its Volt PFA System, designed to treat atrial fibrillation—a common heart condition—has received CE mark approval in Europe. The system uses pulsed field ablation, a technique that delivers high-energy electrical pulses to target problematic tissues in the heart. Earning the CE mark indicates that the product meets strict health, safety, and performance standards, a necessary certification for products sold across the European Economic Area. Since the start of 2025, the stock has surged by over 11%.

In the fourth quarter of 2024, Abbott Laboratories (NYSE:ABT) posted $11 billion in revenue, marking a year-over-year growth of over 7%. While this figure came in just below Wall Street’s forecasts—missing by more than $57 million—the company still showed steady progress over the course of the year. Through 2024, the company reached the high end of its initial forecasts for organic sales growth and adjusted earnings per share. This performance was supported by the company’s continued investment in research and development, which resulted in the introduction of over 15 new growth initiatives during the year, including newly approved products and broader uses for existing therapies.

Abbott Laboratories (NYSE:ABT) currently pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.87%, as of April 15. The company has raised its dividends for 53 years in a row.